12 Peptides Removed from FDA Category 2: What Changed and What's Next

In September 2023, the FDA split bulk drug substances into three categories under its 503A compounding evaluation. Category 1 compounds could keep being compounded. Category 3 compounds were evaluated and permitted. Category 2 was the restriction: substances flagged for 'significant safety or efficacy concerns' that pharmacies could not compound during review.

The effect was immediate. Compounding pharmacies producing BPC-157, TB-500, and other peptides for patients with active prescriptions stopped overnight. Practitioners scrambled for alternatives. The 12 peptides on this list were among the most commonly compounded peptides in the country.

On April 15, 2026, HHS Secretary Kennedy directed the FDA to remove all 12 from Category 2. Each will go to the Pharmacy Compounding Advisory Committee (PCAC) for independent expert review beginning July 2026.

Four peptides in this group target tissue repair through different mechanisms.

A 2025 systematic review screened 544 papers on BPC-157 (PMID 40756949). Thirty-six met inclusion criteria; thirty-five were animal studies. This 15-amino-acid peptide from human gastric juice promotes repair through angiogenesis and nitric oxide modulation. Community evidence fills the gap. Tens of thousands of user reports across Reddit and practitioner networks describe accelerated healing within 2 to 4 weeks. 212 PubMed papers. Safety grade: C.

The first Phase 1 human trial for TB-500 confirmed safety in healthy volunteers (PMID 34346165). This seven-amino-acid fragment of thymosin beta-4 promotes cell migration through actin cytoskeleton remodeling. 172 PubMed citations. Community protocols commonly pair it with BPC-157 for injury recovery. Safety grade: C.

GHK-Cu switches over 4,000 genes toward a repair state (PMID 25789553). Plasma levels of this copper tripeptide drop from 200 ng/mL at age 20 to roughly 80 ng/mL by age 60. Available as both injectable and topical formulations. 162 PubMed papers. Safety grade: A, the highest of any peptide in this group.

KPV enters intestinal cells through PepT1 transporters, making oral dosing a viable route (PMID 18061177). This tripeptide from alpha-MSH shows promising preclinical data for intestinal inflammation. Human studies remain limited. 15 PubMed papers. Safety grade: C.

These three span different pathways. Each has at least one notable human or human-cell study.

A 2025 paper independently confirmed Epithalon's telomere elongation effect in human cell lines for the first time outside Khavinson's lab (PMID 40908429). This synthetic tetrapeptide activates telomerase, the enzyme that adds TTAGGG repeats to chromosome ends. 140 PubMed citations. Safety grade: B.

Skeletal muscle produces 12 times more MOTS-c during exercise than at rest (PMID 33473109). This 16-amino-acid mitochondrial peptide regulates metabolic homeostasis through AMPK activation. Lee's group first described its effects on obesity and insulin resistance in 2015 (PMID 25738459). 100 PubMed papers. Safety grade: B.

Five peer-reviewed randomized controlled trials confirm that MK-677 produces 40 to 60 percent IGF-1 elevation from an oral dose. Technically a non-peptide small molecule, it activates the ghrelin receptor (GHSR-1a). Nass and colleagues ran a 2-year trial in older adults (PMID 18981485). 104 PubMed papers. Safety grade: C.

This group ranges from the well-studied to the controversial.

Semax has 226 PubMed citations and prescription approval in Russia. A single injection at 50 mcg/kg produced a 3-fold BDNF increase in the rat hippocampus (PMID 16996037). It's one of the better-studied nootropic peptides. Safety grade: B. Administered as a nasal spray.

Two key papers supporting Dihexa were retracted in April 2025 for confirmed data fabrication. Athira Pharmaceuticals settled a related False Claims Act case for $4 million. The remaining evidence points to HGF/c-Met pathway activation for cognitive effects. 60 PubMed papers. Safety grade: C. Approach this one with caution.

The largest controlled human study on DSIP enrolled 14 chronic insomniacs in a 1992 double-blind trial (PMID 1299794). Results showed improved delta-wave sleep without REM suppression. Under-studied despite 150 PubMed citations. Safety grade: B.

The Phase IIb HEAL trial tested LL-37 on 148 patients with venous leg ulcers (PMC9298190). The 0.5 mg/mL arm produced a healing rate 6 times higher than placebo (P=0.003). Over 1,000 PubMed papers make this the most-published peptide on the list. Safety grade: B.

Melanotan II activates five melanocortin receptors, producing UV-free tanning, libido effects, and appetite suppression. Dorr's Phase 1 trial confirmed pharmacological activity in 1996 (PMID 8637402). Five published melanoma cases and one renal infarction event sit in the literature. Over 500 Reddit threads document consistent tanning results. Safety grade: C.

The Pharmacy Compounding Advisory Committee (PCAC) is an independent panel of pharmacists, physicians, and scientists that advises the FDA. PCAC will review each of the 12 peptides starting July 2026. At least two meetings are planned for the second half of the year.

Removal from Category 2 is not the same as approval for compounding. PCAC must evaluate each peptide individually, assessing published evidence, manufacturing standards, and clinical use cases. The committee makes recommendations. The FDA makes the final call.

After review, the FDA issues a determination on whether each peptide can be compounded under Section 503A. Some may be cleared. Others may face restrictions or require additional data. The typical timeline from committee review to final FDA decision runs 6 to 12 months.

Pharmaceutical companies may also file new drug applications (NDAs) for specific peptides during this period. If a peptide receives NDA approval, it would move from compounding to standard prescribing with a brand-name product.

Compounding pharmacies still cannot compound these 12 peptides as of today. The announcement removed them from Category 2, but PCAC review and a final FDA determination must happen first.

Patients sourcing peptides from research chemical vendors are in a regulatory gray area. Quality, purity, and sterility of non-pharmaceutical-grade products varies. Always request certificates of analysis (COAs) with HPLC purity and mass spectrometry data from any supplier.

Three things to watch in the coming months. First, PCAC meeting dates and agendas (expected July 2026). Second, any NDAs filed by pharmaceutical companies for specific peptides. Third, state-level pharmacy board guidance on compounding rules during the review period.

Check individual peptide pages on Peptide Schedule for detailed dosing, safety, and evidence profiles. Use the Peptide Calculator to plan doses and the Protocol Builder to create a full protocol with calendar sync. Run the Interaction Checker before combining any peptides.

This content is for educational purposes only. Consult a healthcare provider before using any peptide.